Liminatus Pharma, Inc.
LIMN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001971387
No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $105.1K in total; no superinvestor holds it.
Other share classesLIMNW
Q2 2025 vs. Q1 2025
How the institutions holding Liminatus Pharma, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 0 | 10 | +10 |
| Shares | 0 | 204.7K | +204.7K |
| Value | $0 | $2.28M | +$2.28M |
New holders (10)
Institutions that held Liminatus Pharma, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 73,424 | $818.7K | 0.00% |
| Geode Capital Management, LLC | 63,841 | $711.8K | 0.00% |
| UBS Group AG | 31,486 | $351.1K | 0.00% |
| State Street Corp | 19,000 | $211.8K | 0.00% |
| BlackRock, Inc. | 13,255 | $147.8K | 0.00% |
| Royal Bank of Canada | 2,886 | $32.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 508 | $5.66K | 0.00% |
| Barclays PLC | 184 | $2.05K | 0.00% |
| Bank of America Corp | 66 | $735 | 0.00% |
| SBI Securities Co., Ltd. | 52 | $580 | 0.00% |
Sold out (0)
Institutions that held Liminatus Pharma, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
None.